Topic: Pharmaceuticals

Australian government pushes for jail time in criminal cartel case

Australian prosecutors have argued that the imposition of a custodial sentence on a former manager at an active pharmaceutical ingredient producer who has pleaded guilty to criminal cartel charges is necessary for future deterrence.

16 September 2022

Swiss enforcer raids Novartis over abusive patent litigation

Switzerland’s Competition Commission is working alongside the European Commission to investigate whether Novartis abused one of its patents by launching legal proceedings over a treatment to fight skin disease.

15 September 2022

ALJ finds Illumina/Grail foreclosure concerns unfounded

Illumina is unlikely to try to harm Grail’s rivals because doing so would damage the company’s reputation, the Federal Trade Commission’s administrative law judge has ruled.

13 September 2022

Pennsylvania court: “Overall anticompetitive scheme” alleged in Suboxone litigation

A swathe of claims from direct purchasers, end consumers and state attorneys general accusing Indivior of monopolising the market for opioid addiction treatment Suboxone have survived the pharmaceutical company’s motion for summary judgment.

24 August 2022

Philippines to increase scrutiny of pharmaceutical sector

The Philippine Competition Commission has said it will strengthen enforcement in the pharmaceutical sector following a call from the country’s president to ensure cartels are not contributing to high drug prices.

26 July 2022

Oral hearings not essential for fair appeals, CAT president says

The UK’s Competition Appeal Tribunal can oversee a fair appeal process without holding a hearing, its president has said while rejecting drugmakers' claims that oral submissions are a fundamental part of their appeals against excessive pricing penalties.

25 July 2022

UK tribunal permits hot tubs in excessive pricing appeals

The UK’s Competition Appeal Tribunal has allowed opposing economic experts to testify simultaneously during an upcoming hearing on three companies’ appeals against the national enforcer’s £100 million fine for excessively pricing a thyroid medication.

22 July 2022

CMA reimposes excessive pricing fines on Pfizer and Flynn

The UK’s Competition and Markets Authority has collectively fined drugmakers Pfizer and Flynn Pharma nearly £70 million after an appellate court ordered it to reassess its original decision to punish the companies for excessively pricing a lifesaving anti-epilepsy drug.

21 July 2022

All Servier agreements were by-object restrictions, AG Kokott says

The European Court of Justice should set aside a General Court decision that found agreements between Servier and generics drugmaker Krka did not constitute by-object or by-effect restrictions of competition, EU advocate general Juliane Kokott has said.

14 July 2022

Drugmakers cannot challenge national court decision for disregarding preliminary ruling, ECJ rules

The European Court of Justice has confirmed that member states do not have to let litigants challenge a judicial decision for purportedly ignoring the legal interpretation given by the EU court in a preliminary ruling.

07 July 2022

Unlock unlimited access to all Global Competition Review content